Shares of Vertex Pharmaceuticals Incorporated VRTX were down 11.4% yesterday after the company announced data from a phase II study that evaluated its investigational, oral, highly selective NaV1 ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you